|
Thank you for your role in supporting access to therapeutics in Oregon. The Oregon Health Authority (OHA) appreciates your partnership as we continue navigating the federal allocation process. |
|
Federal Allocations
Week of 4/11/2022:
mAb- Weekly (one week cycle)
- Bebtelovimab: 285
- Evusheld: 2,544 (for Month of April)
Oral antivirals- Weekly (one week cycle)
- Molnupiravir: 528
- Paxlovid: 1,280
|
|
-
Incidence of SARS-CoV-2 Omicron BA.2 variant is increasing in Oregon. The monoclonal antibody Sotrovimab appears to have limited effectiveness against this variant. The federal government has suspended allocation of Sotrovimab.
-
Clinicians should consider other treatments for patients with laboratory-confirmed COVID-19 who are at high risk for severe illness. Options, in order of preference based on guidance from the National Institutes of Health, include Paxlovid (available through allocation from Oregon Health Authority), Remdesivir (available commercially), and either Molnupiravir or Bebtelovimab (both available through allocation from OHA).
-
The federal government has released the Test to Treat Locator to make it easier to find Test to Treat (T2T) locations. This locator allows you to:
-
Enter the appropriate address, city or zip code
-
Select the desired distance from the location entered (in miles)
-
Search locations that include testing, medical assessment by a provider, and dispensing of COVID-19 antivirals (T2T)
-
Search locations to fill a prescription (Federal Retail Pharmacy Therapeutic Program sites included)
IMPORTANT: Please check the locator periodically as sites continue to be added.
-
Please see our Provider Operations Manual, for information on the ordering process, allocation and methodology, cadence, and reporting utilization.
-
Please visit our COVID-19 Therapeutics Landing Page for information and resources on mAbs and antivirals.
-
For all questions or inquiries, please email us at OHA.therapeutics@dhsoha.state.or.us.
|
|
REMINDER: Surveys for Evusheld are currently sent to priority qualifying sites
Product Case Size:
Each product has a specific case size and is outlined below. When ordering, please consider the case size and order accordingly to ensure OHA can fulfill your requests properly.
-
Bebtelovimab - 5
-
Paxlovid - 20 (courses)
-
Molnupiravir - 24 (courses)
Allocation:
For information on oral antivirals allocation process, and to view published federal allocation amounts, please visit: OHA's Antiviral Webpage
Cadence (Excluding Evusheld):
-
Monday - HHS notifies Oregon of our total weekly allotment.
NOTE: HHS informs Oregon of Evusheld’s total allotment monthly, every 4th Monday
-
Wednesday - Orders received by 11:59 p.m. will be allocated in the current week for mAbs and throughout a two-week cycle for oral antivirals.
-
Thursday/Friday - OHA staff will review the requests, determine allotments for each requesting site, and submit orders to AmerisourceBergen via the Health Partner Ordering Portal (HPOP) by Friday.
-
Amerisource Bergen anticipates shipping the products within 4-7 days of order submission.
Utilization reporting:
Utilization reporting is a key component that HHS takes into consideration when determining each state’s allotment. Therefore, it is crucial that each site report their utilization, including for any product redistributed to other sites. Under-utilization and under-reporting will affect Oregon’s future allocations. Please visit Reporting Utilization of COVID-19 Therapeutics for more information.
Track your shipment:
Once your packages are shipped by Amerisource Bergen, you can track them using Track My Shipment Tool.
For oral antivirals shipment tracking, please visit your HPOP account and reference "Therapeutic Shipping."
Thank you,
COVID-19 Response and Recovery Unit
Oregon Health Authority
|
|
|
|
